EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Over Two Years of Sustained Remission With Olaparib Monotherapy in Stage IV Non‐Small Cell Lung Cancer With ATM Mutation: A Case Report

Zhiting Tang iD, Ran Bi iD, Mutasim Idriss iD, Qian Wang iD, Qi Wang iD, Makiko Ban-Hoefen iD

Cancer Reports · 2025

DOI: 10.1002/cnr2.70276 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Cancer Reports, 2025. Verfasst von Zhiting Tang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Unity Hospital, Rochester Regional Health, Rochester, New York, USA. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Piperazines, Phthalazines, Lung Neoplasms. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Ataxia telangiectasia mutated (ATM) mutations represent the most common homologous recombination deficiency (HRD) mutation in non‐small cell lung cancer (NSCLC). However, their therapeutic role in NSCLC has not been established. Case Here, we present a case of a 91‐year‐old male with metastatic NSCLC who progressed on multiple lines of treatment. Next‐generation sequencing revealed ATM mutations, leading to the initiation of olaparib, which successfully achieved remission over a two‐year period.

Conclusion

This case underscores the promising role of olaparib in treating NSCLC with HRD, particularly ATM mutations, highlighting the importance of molecular testing and targeted therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungPiperazinesPhthalazinesLung NeoplasmsAtaxia Telangiectasia Mutated ProteinsPoly(ADP-ribose) Polymerase InhibitorsHumansMaleMutationAged, 80 and overRemission InductionNeoplasm StagingTreatment Outcome

Stichwörter der Autor:innen

ATM mutationNSCLChomologous recombination deficiencyolaparib

Substanzen

olaparibPiperazinesPhthalazinesAtaxia Telangiectasia Mutated ProteinsATM protein, humanPoly(ADP-ribose) Polymerase Inhibitors

Autor:innen und Institutionen

  • Department of Medicine, Unity Hospital, Rochester Regional Health, Rochester, New York, USA.
  • Department of Internal Medicine, Inspira Medical Center Vineland, Vineland, New Jersey, USA.
  • Division of Oncology, Department of Medicine, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, Ohio, USA.
  • Department of Medicine, MetroHealth Medical Center, Case Western Reserve University, Cleveland, Ohio, USA.
  • Division of Hematology and Oncology, Department of Medicine, University of Rochester Medical Center, Rochester, New York, USA.

ORCID-Profile: Zhiting Tang, Ran Bi, Mutasim Idriss, Qian Wang, Qi Wang, Makiko Ban-Hoefen

Zitieren

APA

Tang, Z., Bi, R., Idriss, M., Wang, Q., Wang, Q., & Ban-Hoefen, M. (2025). Over Two Years of Sustained Remission With Olaparib Monotherapy in Stage IV Non‐Small Cell Lung Cancer With ATM Mutation: A Case Report. Cancer Reports. https://doi.org/10.1002/cnr2.70276

Vancouver

Tang Z, Bi R, Idriss M, Wang Q, Wang Q, Ban-Hoefen M. Over Two Years of Sustained Remission With Olaparib Monotherapy in Stage IV Non‐Small Cell Lung Cancer With ATM Mutation: A Case Report. Cancer Reports. 2025. doi:10.1002/cnr2.70276

BibTeX
@article{Tang2025,
  author = {Tang, Zhiting and Bi, Ran and Idriss, Mutasim and Wang, Qian and Wang, Qi and Ban-Hoefen, Makiko},
  title = {Over Two Years of Sustained Remission With Olaparib Monotherapy in Stage IV Non‐Small Cell Lung Cancer With ATM Mutation: A Case Report},
  journal = {Cancer Reports},
  year = {2025},
  doi = {10.1002/cnr2.70276}
}
Kostenlos starten →